SOM0226

About SOM Biotech

SOM Biotech is a Spanish biotech leveraging its proprietary AI platform, SOMaiPRO®, to accelerate drug discovery for rare CNS conditions with high unmet need. The platform has demonstrated strong clinical predictivity, with two identified compounds achieving positive Phase 2a proof-of-concept results. The company's lead program, SOM3355 for Huntington's disease, is poised to enter Phase 3, positioning SOM Biotech as a late-stage clinical development entity. Its strategy combines AI-driven discovery with deep clinical expertise to build a targeted pipeline in valuable, underserved neurological and psychiatric markets.

Therapeutic Areas